Sapacitabine: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in 37 patients showed that sapacitabine

Read the full 160 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE